MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response

• Published in: Brain (London, England : 1878) England : 1878), 2021-09, Vol.144 (8), p.2361-2374
• Main Authors: Pellerin, Kathryn, Rubino, Stephen J, Burns, Jeremy C, Smith, Benjamin A, McCarl, Christie-Ann, Zhu, Jing, Jandreski, Luke, Cullen, Patrick, Carlile, Thomas M, Li, Angela, Rebollar, Jorge Vera, Sybulski, Jennifer, Reynolds, Taylor L, Zhang, Baohong, Basile, Rebecca, Tang, Hao, Harp, Chelsea Parker, Pellerin, Alex, Silbereis, John, Franchimont, Nathalie, Cahir-McFarland, Ellen, Ransohoff, Richard M, Cameron, Thomas O, Mingueneau, Michael
• Format: Article
• Language: English
• Subjects: Agammaglobulinaemia Tyrosine Kinase - metabolism; Animals; Autoantibodies - immunology; Brain - immunology; Brain - metabolism; Brain - pathology; Cell Proliferation - physiology; Mice; Microglia - immunology; Microglia - metabolism; Microglia - pathology; Myelin-Oligodendrocyte Glycoprotein - immunology; Receptors, Fc - metabolism; Spinal Cord - immunology; Spinal Cord - metabolism; Spinal Cord - pathology
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awab231

Autoantibodies are a hallmark of numerous neurological disorders, including multiple sclerosis, autoimmune encephalitides and neuromyelitis optica. Whilst well understood in peripheral myeloid cells, the pathophysiological significance of autoantibody-induced Fc receptor signalling in microglia remains unknown, in part due to the lack of a robust in vivo model. Moreover, the application of therapeutic antibodies for neurodegenerative disease also highlights the importance of understanding Fc receptor signalling in microglia. Here, we describe a novel in vivo experimental paradigm that allows for selective engagement of Fc receptors within the CNS by peripherally injecting anti-myelin oligodendrocyte glycoprotein (MOG) monoclonal antibodies into normal wild-type mice. MOG antigen-bound immunoglobulins were detected throughout the CNS and triggered a rapid and tightly regulated proliferative response in both brain and spinal cord microglia. This microglial response was abrogated when anti-MOG antibodies were deprived of Fc receptor effector function or injected into Fcγ receptor knockout mice and was associated with the downregulation of Fc receptors in microglia, but not peripheral myeloid cells, establishing that this response was dependent on central Fc receptor engagement. Downstream of the Fc receptors, BTK was a required signalling node for this response, as microglia proliferation was amplified in BtkE41K knock-in mice expressing a constitutively active form of the enzyme and blunted in mice treated with a CNS-penetrant small molecule inhibitor of BTK. Finally, this response was associated with transient and stringently regulated changes in gene expression predominantly related to cellular proliferation, which markedly differed from transcriptional programs typically associated with Fc receptor engagement in peripheral myeloid cells. Together, these results establish a physiologically-meaningful functional response to Fc receptor and BTK signalling in microglia, while providing a novel in vivo tool to further dissect the roles of microglia-specific Fc receptor and BTK-driven responses to both pathogenic and therapeutic antibodies in CNS homeostasis and disease.